STEVENSON, Md., April 04, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of Texas on behalf of purchasers of Signet Jewelers Limited (NYSE:SIG) (“Signet” or the “Company”) common stock during the period between August 29, 2013 and February 27, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until May 29, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Signet common stock during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that mounting allegations of sexual harassment by top executives made it unlikely that Signet would escape without paying sizable damages.
According to the complaint, following a February 27, 2017 article detailing the hundreds of cases of sexual harassment by top officials, the value of Signet shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Signet common stock purchased on or after August 29, 2013 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 



